The outcome of allogeneic HSCT in older AML patients is
determined by disease biology and not by the donor type: An
analysis of 96 allografted AML patients >= 50 years from the
Czech acute leukaemia clinical register (alert)

J 2013

The outcome of allogeneic HSCT in older AML patients is determined by disease biology and not by the donor type: An analysis of 96 allografted AML patients >= 50 years from the Czech acute leukaemia clinical register (alert)

JINDRA, P., Jan MUŽÍK, K. INDRAK, P. ZAK, F. A. SABTY et. al.

Základní údaje

Originální název

The outcome of allogeneic HSCT in older AML patients is determined by disease biology and not by the donor type: An analysis of 96 allografted AML patients >= 50 years from the Czech acute leukaemia clinical register (alert)

Autoři

JINDRA, P. (203 Česká republika), Jan MUŽÍK (203 Česká republika, garant, domácí), K. INDRAK (203 Česká republika), P. ZAK (203 Česká republika), F. A. SABTY (203 Česká republika), T. KOZAK (203 Česká republika), Petr CETKOVSKY (203 Česká republika), V. KOZA (203 Česká republika), M. KARAS (203 Česká republika), L. RAIDA (203 Česká republika) a T. SZOTKOWSKI (203 Česká republika)

Vydání

Neoplasma, BRATISLAVA, Slovenská akademie vied, 2013, 0028-2685

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Slovensko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 1.642

Kód RIV

RIV/00216224:14110/13:00069888

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.4149/neo_2013_075

UT WoS

000322501800015

Klíčová slova anglicky

AML; allogeneic HSCT; age; donor

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 25. 10. 2013 11:08, Soňa Böhmová

Anotace

V originále

Older patients with AML have poor prognosis after chemotherapy and allo-SCT was historically limited to the young patients. In the multicentre retrospective study we analyzed 96 consecutive AML patients >= 50 years allografted with related (n=59) or unrelated (n=37) donor. The 2- year OS and DFS rates were 45 % and 42 % for the whole group. The corresponding figures for related patients were 48% and 42% whereas for unrelated 42% and 42%, respectively (OS p=0,721, DFS p = 0,896). The cumulative incidences of relapse (28% of all patients) and NRM mortality (26%) were low with no significant differences among related and unrelated cohorts. Multivariate analysis revealed the only major independent variables associated with an inferior OS were unfavourable cytogenetics (RR 3.36; CI 1.66-6.83; p=0.001) and advanced disease status (RR 2.30; CI 1.21-4.37; p=0.011). Unfavourable cytogenetics (RR 3.00; CI 1.50-5.99; p=0.002) and advanced disease at SCT (RR 2.27; CI 1.22-4.22; p=0.009) were also the only independent variables associated with inferior DFS. In conclusion, our analysis indicates that outcomes of allografted AML patients aged >= 50 years are determined by cytogenetic risk category and disease status at transplantation and not by the type of donor.

Citovat

JINDRA, P., Jan MUŽÍK, K. INDRAK, P. ZAK, F. A. SABTY, T. KOZAK, Petr CETKOVSKY, V. KOZA, M. KARAS, L. RAIDA a T. SZOTKOWSKI. The outcome of allogeneic HSCT in older AML patients is determined by disease biology and not by the donor type: An analysis of 96 allografted AML patients >= 50 years from the Czech acute leukaemia clinical register (alert). Neoplasma. BRATISLAVA: Slovenská akademie vied, 2013, roč. 60, č. 5, s. 576-583. ISSN 0028-2685. Dostupné z: https://dx.doi.org/10.4149/neo_2013_075.

@article{1127152,
   author = {Jindra, P. and Mužík, Jan and Indrak, K. and Zak, P. and Sabty, F. A. and Kozak, T. and Cetkovsky, Petr and Koza, V. and Karas, M. and Raida, L. and Szotkowski, T.},
   article_location = {BRATISLAVA},
   article_number = {5},
   doi = {http://dx.doi.org/10.4149/neo_2013_075},
   keywords = {AML; allogeneic HSCT; age; donor},
   language = {eng},
   issn = {0028-2685},
   journal = {Neoplasma},
   title = {The outcome of allogeneic HSCT in older AML patients is determined by disease biology and not by the donor type: An analysis of 96 allografted AML patients >= 50 years from the Czech acute leukaemia clinical register (alert)},
   volume = {60},
   year = {2013}
}

TY  - JOUR
ID  - 1127152
AU  - Jindra, P. - Mužík, Jan - Indrak, K. - Zak, P. - Sabty, F. A. - Kozak, T. - Cetkovsky, Petr - Koza, V. - Karas, M. - Raida, L. - Szotkowski, T.
PY  - 2013
TI  - The outcome of allogeneic HSCT in older AML patients is determined by disease biology and not by the donor type: An analysis of 96 allografted AML patients >= 50 years from the Czech acute leukaemia clinical register (alert)
JF  - Neoplasma
VL  - 60
IS  - 5
SP  - 576-583
EP  - 576-583
PB  - Slovenská akademie vied
SN  - 00282685
KW  - AML
KW  - allogeneic HSCT
KW  - age
KW  - donor
N2  - Older patients with AML have poor prognosis after chemotherapy and allo-SCT was historically limited to the young patients. In the multicentre retrospective study we analyzed 96 consecutive AML patients >= 50 years allografted with related (n=59) or unrelated (n=37) donor. The 2- year OS and DFS rates were 45 % and 42 % for the whole group. The corresponding figures for related patients were 48% and 42% whereas for unrelated 42% and 42%, respectively (OS p=0,721, DFS p = 0,896). The cumulative incidences of relapse (28% of all patients) and NRM mortality (26%) were low with no significant differences among related and unrelated cohorts. Multivariate analysis revealed the only major independent variables associated with an inferior OS were unfavourable cytogenetics (RR 3.36; CI 1.66-6.83; p=0.001) and advanced disease status (RR 2.30; CI 1.21-4.37; p=0.011). Unfavourable cytogenetics (RR 3.00; CI 1.50-5.99; p=0.002) and advanced disease at SCT (RR 2.27; CI 1.22-4.22; p=0.009) were also the only independent variables associated with inferior DFS. In conclusion, our analysis indicates that outcomes of allografted AML patients aged >= 50 years are determined by cytogenetic risk category and disease status at transplantation and not by the type of donor.
ER  -

JINDRA, P., Jan MUŽÍK, K. INDRAK, P. ZAK, F. A. SABTY, T. KOZAK, Petr CETKOVSKY, V. KOZA, M. KARAS, L. RAIDA a T. SZOTKOWSKI. The outcome of allogeneic HSCT in older AML patients is determined by disease biology and not by the donor type: An analysis of 96 allografted AML patients \&{}gt;= 50 years from the Czech acute leukaemia clinical register (alert). \textit{Neoplasma}. BRATISLAVA: Slovenská akademie vied, 2013, roč.~60, č.~5, s.~576-583. ISSN~0028-2685. Dostupné z: https://dx.doi.org/10.4149/neo\_{}2013\_{}075.

Podrobný výpis o publikaci